News | January 29, 2009

Medtronic Expands CURE-AF Clinical Trial To Aid FDA Approval of Irrigated Ablation With RF

January 29, 2009 - Medtronic Inc. today reported the expansion of its CURE-AF (Concomitant Utilization of Radiofrequency Energy for Atrial Fibrillation) U.S. clinical program with a post-market study in Europe and Canada.

Originally only in the United States, CURE-AF is being conducted to secure FDA Clearance of Cardioblate for the investigational treatment of atrial fibrillation (AF). The program will now collect post-market data internationally on the efficacy of irrigated cardiac ablation with radiofrequency (RF) energy in AF patients.

AF is the most common cardiac arrhythmia, and is associated with a five-fold increase in a patient’s likelihood of suffering a stroke, which can frequently be debilitating and fatal, accounting for one in every 16 American deaths, the company said.

The CURE-AF study is investigating the treatment of AF during an open-heart operation such as valve repair or coronary artery bypass graft (CABG). During the procedure, a surgeon uses Medtronic’s Cardioblate System to create a pattern of transmural lesions, i.e., lesions which span the full thickness of heart tissue. The pattern of lesions is modeled after the highly efficacious Cox Maze procedure. Transmurality of the lesions is required for conduction block, which in turn is essential for the prevention of abnormal conduction associated with AF, and for the potential to restore normal heart rhythm.

The Cardioblate surgical ablation system reportedly achieves consistent transmural lesions with irrigated RF energy. It is currently indicated for cardiac tissue ablation, and has been used in more than 90,000 procedures worldwide.

“We are delighted to be able to join this research effort,” said Dr. Alexander Wahba, professor of cardio-thoracic surgery at St. Olavs University Hospital, Trondheim, Norway. “If successful in its objectives, CURE-AF will allow the introduction of a new treatment option for many patients who otherwise might endure an untreated arrhythmia and the considerable associated risks.”

For mo information: www.medtronic.com

Related Content

Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems| December 08, 2017
December 7, 2017 — Stereotaxis Inc.
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems| May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
CardioFocus, HeartLight Excalibur Balloon, 22nd Annual AF Symposium, atrial fibrillation, initial clinical evaluation
News | Ablation Systems| January 25, 2017
CardioFocus Inc. recently announced the initial clinical evaluation of the HeartLight Excalibur Balloon, a next-...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems| November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Overlay Init